Summary

The North America hepatitis B infection market is expected to reach USD 3.45 billion by 2031 from USD 2.35 billion in 2023, growing at a CAGR of 4.9% in the forecast period of 2024 to 2031.
Market Segmentation:
North America Hepatitis B Infection Market Segmentation, By Type (Chronic and Acute), By treatment (Vaccine, Antiviral Drugs, Immune Modulator Drugs, and Surgery, By Countries (U.S., Canada and Mexico)- Industry Trends and Forecast to 2031

Overview of North America Hepatitis B Infection Market Dynamics:

Driver

• Increasing prevalence of hepatitis B infections
Restraint

• Side effects and drug resistance

Opportunity

• Advanced research and development for clinical trials

Market Players:

The key market players operating in the North America hepatitis B infection market are listed below:

• Gilead Sciences, Inc.
• GSK plc
• Dynavax Technologies
• Bristol-Myers Squibb
• F. Hoffmann-La Roche Ltd

ページTOPに戻る

Table of Contents

1 INTRODUCTION 21
1.1 OBJECTIVES OF THE STUDY 21
1.2 MARKET DEFINITION 21
1.3 OVERVIEW OF NORTH AMERICA HEPATITIS B INFECTION MARKET 21
1.4 MARKETS COVERED 24
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 CURRENCY AND PRICING 28
2.5 DBMR TRIPOD DATA VALIDATION MODEL 29
2.6 MULTIVARIATE MODELLING 32
2.7 THERAPEUTICS LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 VENDOR SHARE ANALYSIS 36
2.11 SECONDARY SOURCES 37
2.12 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHT 43
4.1 PESTAL ANALYSIS 44
4.2 PORTER FIVE FORCES 45
5 NORTH AMERICA HEPATITIS B INFECTION MARKET: REGULATIONS 46
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION 46
5.2 NORTH AMERICA REGULATORY SCENARIO 54
5.3 EUROPE REGULATORY SCENARIO 62
5.4 MIDDLE EAST AND AFRICA REGULATORY SCENARIO 66
5.5 SOUTH AMERICA REGULATORY SCENARIO 71
6 PIPELINE ANALYSIS 76
7 EPIDEMILIOGY 87
8 MARKET OVERVIEW 89
8.1 DRIVERS 91
8.1.1 INCREASING PREVALENCE OF HEPATITIS B INFECTIONS 91
8.1.2 TECHNOLOGICAL ADVANCEMENTS IN DIAGNOSTICS 92
8.1.3 DEVELOPMENT OF COMBINATION THERAPIES FOR HEPATITIS B 93
8.1.4 STRATEGIC INITIATIVES BY COMPANIES FOR HEPATITIS B INFECTION 94
8.2 RESTRAINTS 95
8.2.1 SIDE EFFECTS AND DRUG RESISTANCE 95
8.2.2 INSUFFICIENT VACCINE COVERAGE FOR HEPATITIS B INFECTION 96
8.3 OPPORTUNITY 97
8.3.1 RISING NEW DRUG RELEASES AND INCREASING NEW DRUG PERMITS FOR HEPATITIS B 97
8.3.2 GOVERNMENT PROGRAMS TO RAISE AWARENESS OF HEPATITIS B INFECTION 98
8.3.3 ADVANCED RESEARCH AND DEVELOPMENT FOR CLINICAL TRIALS 99
8.4 CHALLENGES 100
8.4.1 THE COST OF HEPATITIS B TREATMENTS IS HIGH 100
8.4.2 STRINGENT REGULATORY POLICIES AND REGIONAL DISPARITIES IN TREATMENT ACCESS 101
9 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TYPE 102
9.1 OVERVIEW 103
9.2 CHRONIC 106
9.3 ACUTE 106
10 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY TREATMENT 107
10.1 OVERVIEW 108
10.2 VACCINE 111
10.2.1 HOSPITAL PHARMACIES 111
10.2.2 DRUGS STORES AND RETAIL PHARMACIES 111
10.2.3 ONLINE PHARMACIES 111
10.3 ANTIVIRAL DRUGS 112
10.3.1 TENOFOVIR ALAFENAMIDE FUMARATE (TAF) 112
10.3.2 TENOFOVIR DISOPROXIL FUMARATE (TDF) 112
10.3.3 ENTECAVIR 112
10.3.4 OTHERS 112
10.4 IMMUNE MODULATOR DRUGS 113
10.4.1 PEGYLATED INTERFERON 113
10.4.2 INTERFERON ALPHA 113
10.5 SURGERY 114
11 NORTH AMERICA HEPATITIS B INFECTION MARKET, BY REGION 115
11.1 NORTH AMERICA 117
11.1.1 U.S 119
11.1.2 CANADA 121
11.1.3 MEXICO 123
12 NORTH AMERICA HEPATITIS B TREATMENT MARKET: COMPANY LANDSCAPE 125
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS 126
14 COMPANY PROFILE 127
14.1 GILEAD SCIENCES, INC. 127
14.1.1 COMPANY SNAPSHOT 127
14.1.2 REVENUE ANALYSIS 127
14.1.3 COMPANY SHARE ANALYSIS 128
14.1.4 PRODUCT PORTFOLIO 128
14.1.5 RECENT DEVELOPMENT 128
14.2 GLAXOSMITHKLINE PLC 130
14.2.1 COMPANY SNAPSHOT 130
14.2.2 REVENUE ANALYSIS 130
14.2.3 COMPANY SHARE ANALYSIS 131
14.2.4 PRODUCT PORTFOLIO 131
14.2.5 RECENT DEVELOPMENT 131
14.3 DYNAVAX TECHNOLOGIES CORPORATION 133
14.3.1 COMPANY SNAPSHOT 133
14.3.2 REVENUE ANALYSIS 133
14.3.3 COMPANY SHARE ANALYSIS 134
14.3.4 PRODUCT PORTFOLIO 134
14.3.5 RECENT DEVELOPMENTS 134
14.4 F. HOFFMAN-LA ROCHE LTD. 136
14.4.1 COMPANY SNAPSHOT 136
14.4.2 REVENUE ANALYSIS 136
14.4.3 COMPANY SHARE ANALYSIS 137
14.4.4 PRODUCT PORTFOLIO 137
14.4.5 RECENT DEVELOPMENTS 137
14.5 BRISTOL-MYERS SQUIBB COMPANY 138
14.5.1 COMPANY SNAPSHOT 138
14.5.2 REVENUE ANALYSIS 138
14.5.3 COMPANY SHARE ANALYSIS 139
14.5.4 PRODUCT PORTFOLIO 139
14.5.5 RECENT DEVELOPMENTS 139
14.6 ARROWHEAD PHARMACEUTICALS, INC. 140
14.6.1 COMPANY SNAPSHOT 140
14.6.2 REVENUE ANALYSIS 140
14.6.3 PRODUCT PORTFOLIO 141
14.6.4 RECENT DEVELOPMENTS 141
14.7 ARBUTUS BIOPHARMA 142
14.7.1 COMPANY SNAPSHOT 142
14.7.2 REVENUE ANALYSIS 142
14.7.3 PRODUCT PORTFOLIO 143
14.7.4 RECENT UPDATES 143
14.8 AUROBINDO PHARMA 144
14.8.1 COMPANY SNAPSHOT 144
14.8.2 REVENUE ANALYSIS 144
14.8.3 PRODUCT PORTFOLIO 145
14.8.4 RECENT UPDATES 145
14.9 LUPIN PHARMACEUTICALS, INC. 146
14.9.1 COMPANY SNAPSHOT 146
14.9.2 PRODUCT PORTFOLIO 146
14.9.3 RECENT UPDATES 147
14.10 MERCK & CO., INC., 148
14.10.1 COMPANY SNAPSHOT 148
14.10.2 REVENUE ANALYSIS 148
14.10.3 PRODUCT PORTFOLIO 149
14.10.4 RECENT DEVELOPMENTS 149
14.11 NOVARTIS AG 150
14.11.1 COMPANY SNAPSHOT 150
14.11.2 REVENUE 150
14.11.3 PRODUCT PORTFOLIO 151
14.11.4 RECENT DEVELOPMENT 151
14.12 TEVA PHARMACEUTICAL INDUSTRIES 152
14.12.1 COMPANY SNAPSHOT 152
14.12.2 PRODUCT PORTFOLIO 152
14.12.3 RECENT DEVELOPMENTS 152
14.13 ZYDUS PHARMACEUTICALS, INC. 153
14.13.1 COMPANY SNAPSHOT 153
14.13.2 PRODUCT PORTFOLIO 153
14.13.3 REVENUE 154
14.13.4 RECENT DEVELOPMENT 154
15 QUESTIONNAIRE 155
16 RELATED REPORTS 157